Conference Proceedings
Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
F Barlesi, A Drilon, F De Braud, BC Cho, MJ Ahn, S Siena, MG Krebs, CC Lin, T John, DSW Tan, T Seto, R Dziadziuszko, H-T Arkenau, C Rolfo, J Wolf, C Ye, T Riehl, S Eng, RC Doebele
ANNALS OF ONCOLOGY | OXFORD UNIV PRESS | Published : 2019
Open access
Grants
Funding Acknowledgements
Ignyta, Inc., a wholly owned subsidiary of F. Hoffmann-La Roche Ltd.